



Cite this: *Chem. Commun.*, 2016,
52, 8787

Imaging and therapeutic applications of zinc(II)-dipicolylamine molecular probes for anionic biomembranes

Douglas R. Rice, Kasey J. Clear and Bradley D. Smith*

This feature article describes the development of synthetic zinc(II)-dipicolylamine (ZnDPA) receptors as selective targeting agents for anionic membranes in cell culture and living subjects. There is a strong connection between anionic cell surface charge and disease, and ZnDPA probes have been employed extensively for molecular imaging and targeted therapeutics. Fluorescence and nuclear imaging applications include detection of diseases such as cancer, neurodegeneration, arthritis, and microbial infection, and also quantification of cell death caused by therapy. Therapeutic applications include selective targeting of cytotoxic agents and drug delivery systems, photodynamic inactivation, and modulation of the immune system. The article concludes with a summary of expected future directions.

Received 2nd May 2016,
Accepted 9th June 2016

DOI: 10.1039/c6cc03669d

www.rsc.org/chemcomm

Introduction

The primary premise of this feature article is summarized in Scheme 1. That is, anionic membrane surface charge is a biomarker of disease. In mammalian cells, anionic surface charge indicates cell death and dysfunction, signaling vital physiological processes such as dead cell clearance without immune activation and blood clot formation. Many cancer cells expose high levels of an anionic phospholipid that can promote cancer proliferation by suppressing the local immune response. Similarly, the anionic surface of many microbial pathogens

allows them to enter host cells and inhibit the innate immune response for prolonged survival. The strong connection between anionic surface charge and disease has prompted different research programs to create molecular imaging agents and targeted therapeutics for anionic membranes. A major goal of this article is to describe how we approached the problem as a group whose core expertise is small molecule supramolecular chemistry. In general, our research has progressed through an iterative cycle of test tube experiments, cell studies, and pre-clinical evaluation in living subjects. The article is structured in the following order. First, we explain why anionic membrane surface change is considered a biomarker of disease. Then, we describe our research efforts over the last 14 years to develop synthetic zinc(II)-dipicolylamine (ZnDPA) receptors as selective

Department of Chemistry and Biochemistry, 236 Nieuwland Science Hall,
University of Notre Dame, Notre Dame, 46556 IN, USA. E-mail: smith.115@nd.edu




Douglas R. Rice

Douglas Rice was born in Portland, Oregon. He received his BA in Biochemistry from Willamette University in 2010 and his PhD from the University of Notre Dame in 2015. His dissertation research focused on developing molecular imaging strategies for identifying cancer therapeutic efficacy and bacterial infection using targeted nanoparticles and small molecules. Currently, he is developing and studying novel therapeutic agents for parasitic diseases.



Kasey J. Clear

Kasey J. Clear was born in Niles, Michigan. He was awarded his BS in Chemistry in 2011 from Indiana University South Bend, and he completed his PhD in 2016 at the University of Notre Dame. He is currently an Assistant Professor of Chemistry at Murray State University. His research interests include the design and study of synthetic receptors for biologically important anions.



Scheme 1 Anionic membranes are biomarkers of disease.

targeting agents for molecular imaging of cell death and bacterial infection.[†] We also summarize our research to date on several different therapeutic applications using ZnDPA receptors, and we conclude with some comments on likely future directions.

The anionic membrane: a biomarker of disease and microbial pathogens

Cells are surrounded by a plasma membrane that separates the internal cell contents from the external environment and maintains crucial electrochemical energy gradients.^{1,2} In addition, the plasma membrane plays important roles in transmembrane signal transduction and cell–cell communication. The structure of the plasma membrane is a dynamic bilayer composed of different polar lipids and proteins. Many of these amphiphilic compounds have appended carbohydrate chains that protrude from the membrane exterior surface and form the cell glycocalyx.³ About 70% of the polar lipids in a typical mammalian cell plasma membrane are glycerophospholipids, with cholesterol, sphingomyelin, and glycosphingolipids making up the other 30%.¹ The transmembrane distribution of these polar lipids is not symmetrical, with the outer monolayer enriched in zwitterionic phosphatidylcholine (PC)[‡] and

sphingomyelin, and the inner monolayer containing most of the phosphatidylserine (PS), the most abundant anionic phospholipid in the plasma membrane (present in the range of 2–10%).⁴ This transbilayer distribution is maintained in healthy cells by an ATP-dependent translocase that catalyzes the transport of aminophospholipids from the external to the internal membrane surface.⁵ As a result, the electrostatic charge on the membrane exterior surface of a healthy mammalian cell is close to neutral. But during the process of programmed cell death or apoptosis, the translocase activity is attenuated leading to PS exposure and increased negative charge on the cell exterior. The exposed PS can trigger innate immune responses such as recognition and engulfment of dead and dying cells by phagocytes.⁶ This process is responsible for the daily clearance of senescent and damaged cells in the human body. PS exposure also plays an essential role in hemostasis by acting as a key signal in the coagulation cascade.⁷ Upon activation *via* injury to the endothelium, blood platelets expose PS on their outer surface which triggers the attachment of several coagulation factors that execute fibrin synthesis and clot formation.⁸

Excessive cell death beyond the normal level associated with homeostasis is a hallmark of many acute and chronic ailments.⁹ For example, PS exposure occurs during chronic conditions such as cardiovascular disease, or atherosclerosis, which is an inflammatory state characterized by the thickening of artery walls. Atherosclerosis arises from a sustained presence of dead cells in arterial vessels due to an imbalance between apoptosis and phagocytosis. As arterial walls condense, less oxygenated blood can pass into the heart muscle resulting in myocardial ischemia, which causes hypoxia-induced apoptosis in cardiomyocytes. Glaucoma, one of the leading causes of irreversible blindness, is characterized by progressive nerve degeneration and retinal ganglion cell apoptosis.^{10–12} Red blood cell exposure of PS is indicative of stress and dysfunction which typically manifests during an invasion by pathogens such as plasmodium parasites or as a result of blood diseases like sickle cell anemia.^{13,14} Natural PS exposure in red blood cells is identified as a risk factor for stroke and chronic renal failure.¹⁵

With certain diseases such as cancer, the therapeutic goal is to cause cell death, and increased amounts of PS on the cancer cell surface is considered a hallmark of therapeutic success. Even without cytotoxic treatment, exposed PS is a characteristic cell surface feature of many tumors and their surrounding microenvironment. Numerous cancer cells have been reported to expose PS including leukemic cells,¹⁶ neuroblastoma cells,¹⁷



Bradley D. Smith

Bradley D. Smith is Emil T. Hofman Professor of Chemistry and Biochemistry and Director of the Notre Dame Integrated Imaging Facility. His research interests are primarily in the fields of bioorganic and supramolecular chemistry applied to biological systems. A current topic is the creation of molecular probes for detecting and treating cancer and microbial infections.

[†] Several fluorescent ZnDPA probes are commercially available from Molecular Targeting Technologies Incorporated (MTTI, www.mtarget.com) under the brand name PSVue[®]. MTTI has a license agreement with the University of Notre Dame, the employer of B. D. Smith.

[‡] Abbreviations: phosphatidylserine (PS); phosphatidylglycerol (PG); cardiolipin (CL); phosphatidylcholine (PC); phosphatidylethanolamine (PE); zinc(II)-dipicolylamine (DPA); dipicolylamine (DPA); 7-aminoactinomycin (7AAD); *N*-methyl-D-aspartate (NMDA); glycosaminoglycan (GAG); single photon emission computed tomography (SPECT); positron emission tomography (PET); fluorodeoxyglucose (FDG); Förster resonance energy transfer (FRET); 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA); diethylenetriaminepentaacetic acid (DTPA); lipopolysaccharide (LPS); blood–brain barrier (BBB).

malignant melanoma,¹⁸ human gastric carcinoma cells,¹⁹ and others.²⁰ PS exposure is particularly apparent for undifferentiated tumorigenic cells which can express about five times greater PS at their cell surface than their differentiated, non-tumorigenic equivalents.¹⁸ PS is also found in the tumor microenvironment, in the form of tumor-derived microvesicles and on the surface of tumor vasculature, which may promote blood coagulation and fibrin formation to generate a scaffold for tumor growth.^{21–23} Additionally, high PS exposure may promote cancer proliferation by suppressing the local immune response. The interaction between PS-expressing cells and immune cells triggers immunosuppressive pathways that prevent both local and systemic immune activation and cell clearance. There is evidence that cell surface PS suppresses tumor inflammation by inducing secretion of immunosuppressants such as transforming growth factor- β , which inhibits T cell and cytokine production.²⁴ While these pathways are used by apoptotic cells to inhibit potential immune sequelae against 'self', tumors hijack them to enable proliferation.

Similar to cancer cells, obligate intracellular pathogens exploit host cell functions to assure successful entry into host cells to derive nutrients and manipulate cellular machinery for replication. One common strategy is 'apoptotic mimicry' where pathogens mimic apoptotic debris by exposing high fractions of PS on their surface (enveloped PS acquisition) or cloaking themselves in cell-derived PS-containing vesicles (non-enveloped PS acquisition) to facilitate binding, entry and immune evasion. This was first discovered in viruses, which often have a protein capsid surrounded by an outer bilayer membrane.²⁵ Upon fusion with host cells, viruses induce cytopathic effects to delay host cell PS exposure most likely to prevent clearance and enhance virion replication. Subsequent budding from PS-rich organelles, such as the Golgi apparatus, endoplasmic reticulum and lipid rafts, allows PS exposure on newborn virions.^{26–28} Clusters of viruses are packed and released in PS-exposing lipid vesicles, elevating their infectivity. PS-mediated virion uptake also results in the induction of anti-inflammatory cytokine production and inhibition of inflammatory cytokine secretion. Thus, in addition to promoting uptake and binding, apoptotic mimicry by viruses potentiates infection by depleting the host innate immune responses and evading immune recognition. Apoptotic mimicry is utilized by many viral families including vaccinia,²⁹ hepatitis B,³⁰ HIV,³¹ and dengue.³²

Parasitic microorganisms, most notably trypanosomatids, have devised similar methods for entering host tissue.³³ Trypanosomatid parasites exist as either promastigotes (extracellular form within vector insects) or amastigotes (intracellular form responsible for disseminating disease through host cells) and execute two infectious life cycles based on apoptotic mimicry: 'Trojan horse infection' and 'bystander infection'. Trojan horse infection is employed by parasites that naturally expose PS such as *Leishmania donovani* and *Trypanosoma brucei*, the causative parasites for visceral leishmaniasis and Chagas disease, respectively.^{34–38} Upon infection of the host *via* the bite of a carrier insect, PS-exposing promastigotes are engulfed by host neutrophils which are subsequently phagocytosed by

larger macrophages enabling intracellular parasite replication. Smuggling promastigotes within Trojan horse neutrophils not only delivers viable parasites into macrophages but also delays the immune response until the first line neutrophilic response is resolved. Bystander infection is utilized by parasites that do not naturally expose PS, such as *Leishmania amazonensis* and *Trypanosoma brucei*, but instead possess the enzymatic machinery to generate mammalian apoptotic features upon parasite death, most importantly the externalization of PS.³⁹ For viable infection to occur, a sub-population of parasites naturally die within the insect carrier, which enables neutrophil engulfment of both dead and live bystander parasites upon infection.⁴⁰ Alternatively, parasites can migrate with the remnants of PS-exposing apoptotic cells which are also engulfed by neutrophils. Persistent infection and intracellular replication modulate PS exposure on the amastigote form to increase parasite infectivity.³⁵ Another apoptosis-mimicking parasite is *Toxoplasma gondii*, the causative agent of toxoplasmosis. The infective inoculum of *T. gondii* is comprised of two different populations, PS-exposing and non-exposing parasites, that cooperate to establish infection.⁴¹ *T. gondii* is often characterized as the most successful parasite on earth. Approximately one-third of the human population is infected with *T. gondii* with most infections being asymptomatic.^{41,42}


Anionic surface charge is also a ubiquitous feature of the bacterial cell envelope. Bacteria take advantage of phagocytosis in host cells to promote cell-to-cell spread, which was recently discovered in *Listeria monocytogenes*. *L. monocytogenes* emerge from infected macrophages packaged in PS-coated vesicles, which interact with healthy macrophages to facilitate uptake.⁴³ Interestingly, bacterial efferocytosis appears to be an effective mechanism for the host to control *Mycobacterium* species infection, illustrating the fine balance between host cell defense and bacterial infectivity mechanisms.⁴³ Furthermore, most bacterial strains naturally harbor anionic phospholipids such as phosphatidylglycerol (PG) and cardiolipin (CL) within their membrane bilayers.⁴⁴ For example, the lipid membrane of Gram-positive *Streptococcus pyogenes* contains significant fractions of PG (~20%) and CL (~5%).⁴⁵ The *Staphylococcus aureus* membrane contains >60% of PG and CL.^{44,46} Gram-negative *Escherichia coli* contain 9 and 19% PG and CL in their outer membrane and 18 and 40% PG and CL in their inner membrane, respectively.^{47–49} In addition to phospholipids, both Gram-positive and Gram-negative bacteria cell walls have other phosphate containing compounds. The teichoic acids of Gram-positive bacteria contain repeating sugar polymers which are phosphate-linked and can extend 42–50 sugar units in length.⁵⁰ Gram-negative lipopolysaccharide (LPS) harbors lipid A- and O-antigen which contain anionic phosphates.^{51,52} Bacterial spores, survival structures unique to *Bacilli* and *Clostridia* bacteria, contain high quantities of amphiphilic phosphates and carboxylates in their exosporium.⁵³ Networks of negatively charged lipids and polymers help maintain a protective cell envelope and ensure high biofilm integrity.⁵⁴

The realization that anionic charge on the exterior of the cell plasma membrane is a biomarker of disease (or successful

disease treatment) has prompted a search for selective targeting agents that can enable molecular imaging and drug delivery applications.^{55–58} Imaging applications include detection of disease, staging of disease progression, and monitoring the efficacy of therapy, whereas, therapeutic applications include selective targeting of cytotoxic agents and activation of the immune system.^{9,59,60} One targeting approach is to use PS-targeting biomolecules such as antibodies, proteins, or peptides. Examples include the antibody bavituximab,⁶¹ the proteins annexin V⁶² and lactadherin,⁶³ and the C2A domain of the protein synaptotagmin.⁶⁴ The large size of these biological agents enables high selectivity and target affinities, but it also means they are hard to cleanly label with a reporter group. In addition, they may have stability and storage challenges or undesired pharmacokinetic properties such as slow diffusion in restricted sites or slow rates of clearance from the blood pool. Thus, there is a need for small synthetic molecules that can selectively target anionic membranes with easily tunable pharmacokinetic performance. In some cases, simple cationic molecules or nanoparticles have been examined and found to exhibit promising targeting ability.^{65,66} In other cases, synthetic peptides have been uncovered using rational design or screening paradigms and converted into targeted molecular probes.^{67,68} We have contributed to this broad research effort by developing a series of synthetic ZnDPA coordination complexes as low molecular weight targeting agents for anionic membranes, and the next section summarizes the discovery pathway that produced these compounds for imaging and therapy.

Anion recognition using zinc-dipicolylamine (ZnDPA) receptors


Designing molecular hosts for anion recognition in water is a difficult challenge that must overcome numerous obstacles. First, water forms strong hydrogen bonds with anions and any host/guest complexation process must overcome a large energetic penalty to dehydrate the anion and achieve high-affinity association.⁶⁹ Second, anions exist in a wide range of molecular geometries (*e.g.* spherical, linear, trigonal, *etc.*) and selective binding requires a receptor to have a complementary shape. Additionally, many anions are weak acids or bases and effective anion recognition often only occurs within a specific pH window. Anion recognition in complex biomedical environments is especially challenging due to the many competing non-covalent interactions. To date, the most successful synthetic anion receptors are metal coordination complexes that can reversibly bind target anions with dissociation constants in the millimolar to nanomolar range. The basis of these coordination complexes is an organic scaffold that maintains two or more metal centers at an appropriate distance to allow chelation of a bridging guest anion. In general, there are two anion association mechanisms to consider (Scheme 2). In one limiting case, the scaffold binds the metal cations so strongly that the metal/scaffold complex is essentially a single molecular unit with two Lewis acidic sites whose separation is controlled by the length and rigidity of the scaffold (Scheme 2A).




Scheme 2 Modes of anion recognition using divalent metal ion complexes. (A) Receptor with strongly bound metal ions acts as a single molecular unit for anion binding. (B) Three-component assembly process in which both metals bind strongly to the receptor scaffold only in the presence of a suitable complementary anion.

The second association mechanism is when the scaffold has an inherently weak affinity for one or both of the metal cations. However, the presence of a suitable bridging anion induces a three-component assembly process that brings together the scaffold, metal cations, and bridging anion (Scheme 2B). As discussed below, the dipicolylamine (DPA) scaffold can be tuned by structural modification to allow both types of association processes.

The DPA scaffold was reported by Biniecki and Kabzinska in 1964 to have selective affinity for transition metals such as Zn²⁺ (association constant of $\sim 10^7 \text{ M}^{-1}$) over alkali and alkaline metals such as Na⁺, K⁺, Mg²⁺ and Ca²⁺.⁷⁰ The change in DPA molecular orbital energies upon coordination to Zn²⁺ has been exploited extensively over the last two decades as way to design Zn²⁺ sensors.^{71–73} The tridentate DPA coordination leaves an open site on the Zn²⁺ and this Lewis acidic feature has been used to create ZnDPA receptors for anion binding in water (Scheme 2).⁷⁴ Fluorescent ZnDPA chemosensors were pioneered by Hamachi and co-workers, who reported in 2002 that an anthracene derivative with two appended ZnDPA units (**PSVue-380**, Scheme 3)⁷⁵ was a fluorescent sensor of dianionic phosphate derivatives, especially peptides with phosphotyrosine residues. Furthermore, there was a large enhancement of the fluorescence signal upon phosphate association. Mechanistic studies showed that phosphate association with one of the ZnDPA units promotes Zn²⁺ coordination to the second DPA and loss of a photoinduced





Scheme 4 Anionic membrane recognition using ZnDPA receptors. (A) Three-component assembly process for membrane recognition of anionic phospholipids. (B) Structural representation of complexation between anionic PS and ZnDPA receptor.

electron transfer (PET) quenching effect.⁷⁶ Various ZnDPA complexes have been designed over the intervening years for aqueous sensing of other phosphate containing molecules with association constants ranging from 10^5 to 10^7 M⁻¹.^{75–80} This work has been described in review articles,^{81,82} and it remains an active research topic.^{83–85} In addition, other metal coordination complexes, such as zinc cyclen complexes, have been developed for effective phosphate recognition, and the interested reader is directed to review articles that describe these valuable systems.⁸² A technical advantage with synthetic zinc coordination complexes is the relative ease in which they can be converted into oligomers with multiple phosphate binding sites. As discussed below, this strategy creates multivalent receptors that can recognize anionic surfaces with altered association thermodynamics and kinetic properties due to cooperativity effects such as enhanced local concentration and binding additivity.⁸²

In 2003 we were looking for a synthetic receptor to target anionic membrane surfaces, and we decided to investigate **PSVue-380**.⁸⁶ The fluorescence intensity of **PSVue-380** was found to increase by 10-fold when titrated with anionic vesicles that contained PS, PG, or phosphatidic acid, but was unchanged when treated with vesicles comprised solely of the zwitterionic PC.⁸⁷ Association of the sensor with the membrane surface occurs by a 'three component' self-assembly process where the DPA scaffold containing one Zn²⁺ ion and a free Zn²⁺ ion are attracted to the negatively charged membrane surface and form a bridged complex with the anionic head group of a phospholipid (Scheme 4). The successful targeting of model vesicle systems prompted us to evaluate whether **PSVue-380** could operate in more complicated biological environments.

Molecular imaging of dead and dying cells











We initially explored fluorescent ZnDPA probes for detecting cell death in cultured cell samples using cell microscopy or

flow cytometry. Cell-based tests that can quantify levels of cell death are broadly useful for fundamental biomedical research and drug development. Early studies with **PSVue-380** found that it was a selective stain for apoptotic cells,⁸⁶ but the blue fluorescence emission wavelength (380/440 nm) was a technical limitation since it overlapped with cell background autofluorescence. We subsequently designed ZnDPA sensors using a receptor–linker–reporter approach that linked a ZnDPA complex (anion receptor) to a signaling unit (typically a fluorophore) (Table 1).^{88,89} The green emitting **PSVue-480** was evaluated using cancer cells treated with the drug camptothecin to induce apoptosis. Simultaneous treatment with **PSVue-480** and the nuclear stain 7-aminoactinomycin D (7AAD) allowed identification of early-apoptotic cells (with impermeable plasma membranes) due to selective staining with **PSVue-480** and exclusion of 7AAD (Fig. 1A). Flow cytometry analysis of the same cell populations showed that approximately 30% of the cells were apoptotic or necrotic and thus stained with **PSVue-480** (Fig. 1B).

Another pre-clinical application of ZnDPA probes is to enable molecular imaging of cell death in animal models of disease and disease treatment. Detecting dead and dying cells in a living organism is quite challenging because the cell death process is a time-dependent phenomenon. The amount of probe accumulation at cell death sites in a living animal depends on the rate and location of the cell death process as well as the rate of dead cell clearance by the animal's innate immune response. The challenge is compounded by the limitations of fluorescence imaging with visible light, which suffers large signal loss due to scattering/attenuation by the animal tissue. Thus, animal studies with green emitting **PSVue-480** can only be conducted on superficial sites that can be directly illuminated, such as the interior of the eye. An example of this type of study was recently performed by Kwong and coworkers who determined that **PSVue-480** could label retinal ganglion cells undergoing apoptotic degeneration induced by *N*-methyl-D-aspartate (NMDA).⁹⁰ Adult rats were given intravitreal injections of NMDA followed by euthanasia at various time points. One hour before euthanasia, **PSVue-480** was intravitreally injected followed by imaging of the treated eye. Fluorescence labeling was observed in the retinas at one hour and up to 24 hours following NMDA treatment. Targeting of exposed PS on the apoptotic retinal neurons occurred earlier than detection of DNA fragmentation, indicating the potential of ZnDPA probes for tracking the early stages of degenerating retinal neurons.

It is well-known that light penetration through skin and tissue is a maximum when the wavelength is in the near-infrared window of 650 and 900 nm.⁹¹ Therefore, *in vivo* imaging performance was greatly improved by developing the near-infrared ZnDPA probe **PSVue-794** with an appended carbocyanine fluorophore. Cell death imaging studies focused initially on two *in vivo* tumor models that spontaneously developed foci of necrotic cells in the tumor cores, namely, immunocompetent Lobund-Wistar rats with PAIII prostate tumors, and athymic nude mice containing EMT-6 mammary tumors.⁹² Whole-body optical imaging of tumor-bearing animals dosed with **PSVue-794** found that the probe selectively targeted the tumor core.

Table 1 ZnDPA imaging and affinity probes

					
Name	Reporter structure	Uses and references	Name	Reporter structure	Uses and references
PSVue-480		Imaging cell death ^{88–90}	mSeek		Imaging leishmania ¹³⁶ bacteria ¹³⁷
PSVue-643		Imaging bacteria ¹¹⁷ cell death ¹⁰⁵	mDestroy		Photoinactivation bacteria ¹³⁷
PSVue-794		Imaging cell death ^{92,95} cancer therapy ^{93,94} arthritis ^{96,97} bacteria ¹¹⁶	ZnDPA-[¹¹¹ In] DOTA		Imaging bacteria ¹²⁵
PSVue-Biotin		Imaging bacteria ^{124,129}	ZnDPA-[¹¹¹ In] DTPA		Imaging bacteria ¹²⁵
			bis-ZnDPA-[¹¹¹ In] DTPA		Imaging bacteria ¹²⁵

Probe accumulation in the PAIII prostate tumors was 36-fold higher than an untargeted control fluorophore. *Ex vivo* bio-distribution and histological analyses showed **PSVue-794** targeting to the interior necrotic regions of the tumors (Fig. 1C). Similarly, **PSVue-794** accumulation in the EMT-6 mammary tumors was 18-fold higher than the control fluorophore.

These results led to the development of **PSVue-794** as a commercial fluorescent probe for pre-clinical imaging,[†] and it is now finding increasing use in a broad range of applications. Several studies have employed **PSVue-794** to monitor tumor cell death induced by different therapeutic treatments. Rats bearing PAIII prostate tumors were given a focal beam of radiation which induced rapid apoptosis and necrosis at the irradiation site.⁹³ Subsequent dosing with **PSVue-794** followed by whole-body imaging showed probe accumulation in a radiation-treated tumor over a non-treated tumor on the same animal (Fig. 1D). To simulate cell death generated by chemotherapeutic

treatment, separate cohorts of healthy rats were dosed with dexamethasone, a glucocorticoid that induces selective cell death at the thymus, followed by dosing with **PSVue-794** twenty-four hours later. *Ex vivo* imaging of organs showed thymus uptake of **PSVue-794** was four times higher than a control fluorophore. Palmowski and coworkers conducted a comparative study of cell death imaging performance after antiangiogenic therapy and found that apoptosis was detected significantly better with the low molecular weight **PSVue-794** than with the dye-labeled protein probe annexin V.⁹⁴

Cell death detection due to physical injury was examined in a murine traumatic brain injury model. Traumatic brain injury is characterized as acute cranial tissue damage that leads to secondary processes such as cell death and blood–brain-barrier disruption. The ability of **PSVue-794** to detect cranial cell death was tested using a cryolesion mouse model that conditionally mimics features of human brain injury.⁹⁵ In short, the model




Fig. 1 (A) Fluorescence micrographs of Jurkat cells treated with camptothecin (10 μM) for 3.5 h to induce apoptosis, then stained with **PSVue-480** (green, 5 μM) and 7AAD (red, 500 ng mL^{-1}). (B) Flow cytometry histograms illustrating staining of Jurkat cells by **PSVue-480** and 7AAD. A and B reprinted with permission from ref. 89. © 2005 John Wiley and Sons. (C) X-ray and fluorescence overlay image of a rat prostate tumor model at 24 h postinjection of **PSVue-794**. Reprinted with permission from ref. 92. © 2010 American Chemical Society. (D) *Ex vivo* epifluorescence image of a rat bearing two subcutaneous PAIII prostate tumors and dosed with **PSVue-794**. The right flank tumor received focal beam radiation therapy, and the left flank tumor was not treated. Reprinted with permission from ref. 93. © 2011 Springer. (E) Whole body fluorescence image of a mouse with induced arthritis given a single dose of **PSVue-794** 48 hours prior to imaging. Arrows point to arthritic feet joints. Reprinted from open access ref. 96. (F) Decay-corrected transaxial and coronal [^{18}F]-ZnDPA PET images of a rat following acute myocardial infarction and 60 min after subsequent probe injection. The short red line indicates the location of the heart. Reprinted from open access ref. 101.

involves brief contact of a cold rod to the head of a living, anesthetized mouse, which triggers localized cell death at the contact site. Whole-body fluorescence imaging of **PSVue-794** permitted visualization of the cryolesion as well as longitudinal monitoring of healing process over a one week period. **PSVue-794** has also been used for arthritis imaging⁹⁶ and optical imaging of articular cartilage degeneration.⁹⁷ Arthritis is a chronic inflammatory state caused by neutrophil and macrophage infiltration at skeletal joints, counterbalanced by apoptosis of the activated immune cells leading to termination of the inflammatory response.⁹⁸ **PSVue-794** was assessed for the non-invasive molecular imaging of rheumatoid arthritis *via* metabolic function in murine collagen-induced arthritis. DBA/1 mice were intravenously treated twice with chicken collagen type II in Freund's adjuvant which generates skeletal inflammation and arthritis that was easily monitored at the mouse footpad. Fluorescent emission from arthritic and non-arthritic mice treated with **PSVue-794** correlated reliably with the degree of footpad swelling and the manifestation of arthritis, illustrating a useful and economical alternative method for non-invasively assessing arthritis in murine models (Fig. 1E). One factor that contributes to arthritis is the degradation of cartilage, a flexible connective tissue at the joints. An early signal of cartilage degradation is the loss of negatively charged glycosaminoglycans


(GAGs), which play an essential role in generating supportive pressure in the collagen matrix. The feasibility of **PSVue-794** for optical imaging of cartilage degeneration was tested using mice with young and aged knee joints. *Ex vivo* imaging of cartilage treated with **PSVue-794** showed high probe accumulation on young cartilage compared with aged cartilage indicating a change of the level of GAGs. Optical imaging of young and old mice further indicated that **PSVue-794** demonstrated higher uptake and retention in young mice (high GAGs) than old mice (low GAGs) when administrated *via* local injection in mouse knee joints. In a surgically induced osteoarthritis model, dramatically higher **PSVue-794** signal was observed in sham joints (high GAGs) than osteoarthritis joints, demonstrating the ability of **PSVue-794** for visual detection of early degeneration of cartilage in living subjects.

The promising fluorescence imaging results in living animals prompted the design of radiolabeled ZnDPA complexes with greater signal tissue penetration and potential for clinical translation. Wyffels and coworkers labeled a ZnDPA targeting unit with gamma-emitting technetium-99m ($^{99\text{m}}\text{Tc}$) in two different forms, [$^{99\text{m}}\text{Tc}(\text{CO})_3$] $^{3+}$ and [$^{99\text{m}}\text{Tc}$ -HYNIC].⁹⁹ The two $^{99\text{m}}\text{Tc}$ -labeled probes were tested in mice that had been treated with anti-Fas antibody which induced rapid and massive hepatic apoptosis. Single-photon emission tomography and computed tomography


(SPECT/CT) imaging studies showed significantly greater accumulation of both probes in the livers of antibody-treated mice compared to mice given no treatment. Furthermore, the increased liver uptake of the $[^{99m}\text{Tc}(\text{CO})_3]^{3+}$ conjugate was comparable to radiolabeled annexin V. Mice with an induced myocardial ischemia-reperfusion injury were used as a second model to demonstrate the sensitivity of the ^{99m}Tc -labeled tracers for apoptotic and necrotic tissue. Myocardial ischemia was produced by ligation of the left coronary artery for thirty minutes, followed by two hours of reperfusion. At the end of reperfusion, rats were injected intravenously with tracer followed by euthanasia and removal of organs two hours later for scintillation counting. Selective accumulation of both probes was observed in mice with myocardial ischemia-reperfusion injury; however, the absolute tracer uptake in the damaged myocardium was low and likely would have been undetectable by *in vivo* cardiac imaging.

Positron emission tomography (PET) imaging of cell death has been explored using ZnDPA covalently labeled with the positron-emitting isotope, ^{18}F .¹⁰⁰ Wang *et al.* reported *in vivo* PET imaging experiments using two different ^{18}F -labeled ZnDPA probes and ^{18}F -fluorodeoxyglucose (^{18}F -FDG) in separate cohorts of hepatocellular carcinoma-bearing mice with and without cytotoxic doxorubicin treatment. ^{18}F -FDG showed no significant uptake change before and after chemotherapy, indicating that ^{18}F -FDG lacked specificity to monitor anticancer therapy. In contrast, one of the ^{18}F -ZnDPA probes accumulated significantly in the doxorubicin-treated tumors compared to untreated control tumors. Recently, a similar ^{18}F -ZnDPA analog was synthesized and evaluated for noninvasive imaging of cardiomyocyte apoptosis following acute myocardial infarction.¹⁰¹ PET imaging showed significant cardiac accumulation of the probe in rats following infarction which was consistent with histological evidence of cardiac cell death (Fig. 1F).

Translation of ZnDPA probes to the clinic for cell death imaging would be facilitated if the probes exhibited higher affinity and selectivity for dead and dying tissue. The simplest way to increase probe affinity is to attach multiple recognition elements to a single scaffold and create a multivalent probe (Scheme 5). This strategy was explored using an fluorescent near-infrared dye scaffold with two (**bis-ZnDPA-SR**) or four (**tetra-ZnDPA-SR**) appended ZnDPA units.¹⁰² Vesicle titration assays showed that **tetra-ZnDPA-SR** exhibited higher selectivity than **bis-ZnDPA-SR** for anionic PS/PC vesicles over zwitterionic PC vesicles. Both probes selectively targeted dead and dying cells, but there was a marked difference in the cell microscopy images. The **tetra-ZnDPA-SR** localized strongly at the cell plasma membrane, whereas the **bis-ZnDPA-SR** distributed throughout the cytosol. The fluorescent probes were tested in three animal models of cell death, and in each case there was more **tetra-ZnDPA-SR** accumulation at the site of cell death than **bis-ZnDPA-SR** supporting the general hypothesis that increasing the number of ZnDPA units improves the cell death targeting ability. Unfortunately, the multivalent probes showed a tendency to undergo cross-linking and self-aggregation, which produced undesired pharmacokinetic properties including high off-target




Scheme 5 Multivalent ZnDPA probes. (A) Bivalent and tetravalent probes containing near-infrared fluorescent squaraine rotaxane reporter groups. (B) Liposome-anchored multivalent ZnDPA probe.



Scheme 6 (A) Strategy for improving ZnDPA affinity for PS (red) through covalent modification of the targeting group with urea groups (green). (B) Structure of lead compound discovered by screening a library of ureido modified ZnDPA receptors.

organ accumulation. This led to us to pursue an alternative design strategy for enhancing PS affinity; that is, a single ZnDPA scaffold with appended functional groups that are capable of forming secondary noncovalent interactions with the PS headgroup (Scheme 6).¹⁰³ A focused 25-member library of modified dipicolyl-amine units with different appended 2-amido substituents were synthesized and screened for affinity to PS-rich membranes using a rapid equilibrium dialysis assay.¹⁰⁴ The screening identified a lead candidate with two lipophilic phenethyl ureido groups (**PU-ZnDPA**), which was converted into a deep-red fluorescent probe and compared with an unmodified ZnDPA probe (**PSVue-643**) in a series of FRET-based vesicle titration studies, cell microscopy experiments, and *in vivo* rat tumor biodistribution measurements. The cell microscopy showed that **PU-ZnDPA** possessed comparatively higher affinity for dead and dying cells. However, the *in vivo* experiments indicated undesirable high uptake of **PU-ZnDPA** in the liver, spleen and intestines.

With the aim of improving *in vivo* pharmacokinetics, we subsequently examined molecular imaging probes based on phenoxide-bridged ZnDPA structures.¹⁰⁵ More specifically, we evaluated a scaffold derived from L-tyrosine (Scheme 7), which had been employed previously for phospholipid translocation across model bilayer membranes and protein labeling.^{106–109} Monovalent (**mono-T-ZnDPA**) and bivalent (**bis-T-ZnDPA**) deep-red fluorescent probes were synthesized and compared to earlier **PSVue-643** for targeting performance and *in vivo* biodistribution properties. Studies using liposomes showed that the bivalent probe **bis-T-ZnDPA** had a higher affinity for PS-rich membranes compared to the monovalent probe **mono-T-ZnDPA**, but **bis-T-ZnDPA** exhibited fluorescence self-quenching at the membrane surface, a feature that was also apparent in cell imaging experiments.



Scheme 7 Structures of monovalent and bivalent T-ZnDPA probes built from L-tyrosine derived scaffold.

The *in vivo* biodistribution of **mono-T-ZnDPA** was very impressive with relatively high targeting of dead and dying tissue and low off-target accumulation in other organs. An analogous, radioactive ¹¹¹In-labelled version, **mono-T-ZnDPA-[¹¹¹In]DTPA** was prepared and found to also exhibit a clean biodistribution profile making it a promising candidate for further development as a clinical imaging probe of cell death.

Molecular imaging of bacteria

There is a need for fluorescent molecular probes that can detect very small numbers of pathogenic bacterial cells in food, drinking water, or biomedical samples.^{110–112} The ability of ZnDPA probes to selectively target bacteria was first discovered using **PSVue-380**.¹¹³ Fluorescence microscopy of bacteria treated with **PSVue-380** showed strong staining of both Gram-negative *Escherichia coli* and Gram-positive *Staphylococcus aureus* bacterial cells with a large enhancement in fluorescence emission intensity upon binding (Fig. 2A). The fluorescent probes appeared to preferentially bind the cell membrane over the intracellular DNA. Also, **PSVue-380** could selectively stain bacterial cells in the complex biological medium of saliva without staining off-target mammalian cells (Fig. 2B). Ganesh and co-workers subsequently reported that **PSVue-380** has high affinity for bacterial LPS, a primary component of the outer membrane of Gram-negative bacteria and a potent stimulant of the mammalian immune response.¹¹⁴ Studies of other ZnDPA probe designs have consistently demonstrated high affinity for the anionic surfaces of bacteria.¹¹⁵

The selective bacterial staining led us to explore non-invasive imaging of localized infection sites within living mice using **PSVue-643** or **PSVue-794**.^{116,117} These studies employed a straightforward leg infection model in which a bolus of bacteria was injected into the mouse thigh and allowed to incubate for several hours, followed by injection of the molecular probe into the tail vein and whole-body imaging twenty-four hours later. Target-to-Non-Target (T/NT) ratios were measured by taking region of interest measurements at the infected and uninfected leg. The representative fluorescence image in Fig. 2D shows the distribution of **PSVue-794** in a mouse with a leg infection of Gram-positive *S. aureus*.^{116,117} The fluorescent probe cleared slowly from the bloodstream and the T/NT ratio reached four at 21 h postinjection of the probe. Histological samples taken from the infection site indicated that the **PSVue-794** probe targeted the bacteria cells and not the dead and dying mammalian cells that surrounded the infection site. Improved fluorescence imaging probes with high bacterial affinity were designed using brighter and more photostable squaraine rotaxane dyes.^{118,119} These probes were more hydrophilic and washed out more rapidly from the blood clearance organs. Whole-animal optical imaging showed co-localization of the fluorescent ZnDPA probe signal with the bioluminescence signal from a genetically engineered strain of *Salmonella enterica* serovar typhimurium (*S. enterica*) (Fig. 2E). Furthermore, there was no accumulation of the ZnDPA probes in sites of sterile inflammation induced by injection of λ -carrageenan. These *in vivo* studies showed that fluorescent ZnDPA probes




Fig. 2 (A) Epifluorescence microscopy of planktonic *E. coli* (–) after incubation with **PSVue-380** (10 μ M). (B) Saliva sample containing human epithelial cells (stained red) with an associated 'clump' of bacteria stained with **PSVue-380** (blue). A and B reproduced with permission from ref. 113 © Royal Society of Chemistry. (C) Fluorescence microscopy image of human A-549 cells and *E. coli* K12 (–) cell mixtures were stained with DAPI (1 μ g mL^{–1}), and treated 15 min later with **tetra-ZnDPA-SR**. (D) Optical image of a mouse with a *S. aureus* infection in the left rear leg at 21 hours after intravenous injection of **PSVue-794**. Reprinted with permission from ref. 116. © 2006 American Chemical Society. (E) Whole-body fluorescence and bioluminescence imaging of an athymic mouse containing a leg infection of bioluminescent *S. enterica* serovar typhimurium FL6 (–) and imaged 3 hours after dosage with **tetra-ZnDPA-SR**. Reprinted with permission from ref. 119. © 2010 American Chemical Society. (F) SPECT/CT image of a mouse with a leg infection of *S. pyogenes* and imaged 20 hours post-administration of **bis-ZnDPA-[¹¹¹In]DTPA**. Reproduced with permission ref. 125. © 2015 Springer.

were not highly sensitive imaging agents (the localized infection site had to contain at least $\sim 10^6$ colony forming units for fluorescence visualization), but they were remarkably selective for bacterial cells.

Collectively, these results have encouraged efforts to develop radiolabeled ZnDPA conjugates for clinical imaging. Clinical detection of bacterial infections is crucial for immunosuppressed patients and patients with prosthetic devices due to their increased vulnerability to relatively nonvirulent microorganisms.¹²⁰ It has been recognized for some time that noninvasive imaging technology will greatly facilitate the process of infection diagnosis.^{121–123} Liu *et al.* first produced radiolabeled ZnDPA for nuclear imaging of infection in mice using a streptavidin protein that can bind biotinylated reagents.¹²⁴ Biotinylated ZnDPA (**PSVue-Biotin**) and the biotinylated reporter ¹¹¹In-DOTA were linked to the streptavidin. The nuclear probe was tested in mice injected intramuscularly with *Streptococcus pyogenes* (infection model) or with lipopolysaccharide (inflammation model). Cohorts were injected intravenously with the probe followed by periodic SPECT/CT imaging which displayed rapid and selective accumulation at the site of *S. pyogenes* infection. The ¹¹¹In T/NT ratio was 2.8 fold higher in infection bearing animals compared to sterile inflammation animals, demonstrating that ZnDPA targeting can accurately distinguish

bacterial invasion. Our lab subsequently prepared two monovalent radiolabeled tracers, **ZnDPA-[¹¹¹In]DTPA** and **ZnDPA-[¹¹¹In]DOTA**, each with a single ZnDPA targeting unit, and a bivalent tracer, **bis-ZnDPA-[¹¹¹In]DTPA**, and tested them in the same *S. Pyogenes* infection model.¹²⁵ All three [¹¹¹In]-ZnDPA tracers selectively targeted the *S. Pyogenes* infection with the highest target selectivity observed with divalent **bis-ZnDPA-[¹¹¹In]DTPA**. Clearance of the divalent tracer from the bloodstream was slower and primarily through the liver and the T/NT ratio rose to six after 20 h. The SPECT/CT imaging indicated the same large difference in tracer pharmacokinetics and higher accumulation of the divalent tracer at the site of infection (Fig. 2F). The tracer pharmacokinetics depended heavily on tracer molecular structure suggesting that it is possible to fine tune the structural properties for optimized *in vivo* imaging performance and clinical translation. Additionally, Matosziuk *et al.* designed a ZnDPA magnetic resonance contrast agent consisting of ZnDPA targeting unit conjugated to a gadolinium chelate. *In vitro* studies with *S. aureus* and *E. coli* show that the ZnDPA contrast agent efficiently labeled bacteria compared to a gadolinium control.¹²⁶ The ZnDPA probe also significantly reduced the *T*₁ relaxation time of labeled bacteria, thus enhancing magnetic resonance image contrast and illustrating the potential for visualizing bacterial infections using whole body MR imaging.

As stated above, clinical translation of ZnDPA imaging agents would be facilitated if the probes exhibited higher target affinity, and one design strategy is to create multivalent probes. To date, we have prepared and studied the bacteria binding properties of multivalent and dendritic probe architectures with four to thirty-two ZnDPA units, and found them to act as broad-spectrum bacterial agglutination agents.¹²⁷ The multivalent probes rapidly cross-linked ten different strains of bacteria, regardless of Gram-type and cell morphology. A fluorescent probe with four ZnDPA units (**tetra-ZnDPA-SR**) was found to target an infection site in a living mouse. The therapeutic potential of multivalent ZnDPA probes as bacteria agglutination agents is discussed further in the next section. The potential of these probes as reporters of cell surface structure was raised by an early bacterial imaging study using CdSe/ZnS core/shell quantum dots coated with **PSVue-Biotin**.¹²⁸ Bacterial staining with these extremely bright fluorescent imaging probes was observed to be sensitive to the cell surface topology. For example, there was no staining of smooth *E. coli* strains with wild type LPS and extended O-antigen polysaccharides which prevented access of the relatively large nanoparticles to the phosphorylated lipid A buried in the outer membrane. Conversely, there was strong staining of a rough *E. coli* mutant that lacked the O-antigen element.

Therapeutic applications using ZnDPA complexes

Intracellular delivery of macromolecular therapeutics is an important unsolved clinical challenge, particularly for RNA-based treatments (e.g., siRNA, miRNA or oligonucleotides) which are rapidly degraded by tissue enzymes. Recently, Choi *et al.* applied ZnDPA complexes for the delivery of siRNA by

exploiting the selective affinity of ZnDPA for the phosphodiester groups on the siRNA backbone.¹²⁹ ZnDPA complexes were covalently conjugated to hyaluronic acid-based nanoparticles to enable efficient tumor-targeted delivery of RNAs and small-molecule drugs.¹³⁰ ZnDPA-coated nanoparticles were loaded with siRNA specific for a bioluminescence gene within cancer cells and tested in a mouse colon cancer model. Bioluminescent intensities from tumors treated with RNA-delivering nanoparticles showed a substantial decrease in signal 24 h after injection, demonstrating substantial promise for drug delivery.

The bacterial targeting properties of ZnDPA-coated nanoparticles makes them an attractive platform for different types of therapeutic strategies. For example, iron oxide nanoparticles coated with ZnDPA units were designed for the physical removal of bacteria from the bloodstream. Bacterial sepsis is a serious clinical condition that can lead to multiple organ dysfunction and death despite timely treatment with antibiotics and fluid resuscitation. Lee *et al.* developed ZnDPA-conjugated magnetic nanoparticles and used them for highly selective and rapid separation of bacteria and potentially their endotoxins from whole blood.¹³¹ Custom magnetic microfluidic devices were found to remove *E. coli* bound to the nanoparticles at flow rates as high as 60 mL h⁻¹, resulting in almost 100% clearance (Fig. 3A). In principle, such devices could be adapted to clear bacteria from septicemic patients.

Our group has pursued two different therapeutic ideas using nanoscale liposomes and ZnDPA complexes. In one approach, we prepared liposomes coated with PEG chains terminating with ZnDPA affinity units (Scheme 5B) and found that they selectively agglutinated bacterial cells in the presence of healthy human cells. PEGylated liposomes are known to collect in sites of bacterial infection within living subjects and additional bacteria-specific ligands on the liposome surface should conceivably enhance the accumulation.^{132,133} While not bactericidal, the

multivalent liposomes may have value as immobilization agents that sequester an infection and perhaps deliver antibiotic cargo. Our second idea is a two-step liposome delivery and triggered drug release strategy. In short, ZnDPA complexes are used to chemically trigger drug release from anionic liposomes that are pre-targeted to a site of disease (Fig. 3B). Proof-of-concept studies have shown that certain ZnDPA structures such as **PU-ZnDPA-Trigger** (Scheme 6) are very effective at releasing dyes¹³⁴ or prodrugs¹³⁵ from liposomes with membranes containing 5 mol% of anionic PS.

Not surprisingly, some ZnDPA compounds have been found to have antibiotic activity, especially against Gram-positive bacteria such as *S. aureus* with a minimum inhibitory concentration of 1 µg mL⁻¹. Preliminary mechanism studies suggest that the mode of action is depolarization of the bacterial membrane. An exciting new discovery is that ZnDPA compounds have selective activity against the trypanosomatid parasite *L. Major*, a causative agent of the neglected tropical disease cutaneous leishmaniasis.¹³⁶ Modern treatment regimens rely on a small number of chemotherapeutics with serious side effects and there is a need for more effective alternatives. Fluorescence microscopy of *L. major* promastigotes treated with a fluorescently labeled ZnDPA probe indicated rapid accumulation of the probe within the axenic promastigote cytosol. Selective antileishmanial activity was observed with eight ZnDPA complexes against *L. major* axenic promastigotes with 50% effective concentrations (EC₅₀) values in the range of 12.7–0.3 µM. *In vivo* treatment efficacy studies showed that a ZnDPA treatment regimen reduced the parasite burden nearly as well as the reference care agent, potassium antimony(III) tartrate, and with less necrosis in the local host tissue (Fig. 3C). The results demonstrate that ZnDPA coordination complexes are a promising new class of antileishmanial agents with potential for clinical translation.




Fig. 3 (A) Magnetophoretic separation of green-fluorescent *E. coli* (–) from whole blood after pre-treatment with iron oxide nanoparticles coated with ZnDPA using a surrounding magnet within a microfluidic device. Reprinted with permission from ref. 131. © 2014 American Chemical Society. (B) Selective triggered drug release using ZnDPA association with anionic liposomes causing rapid leakage of encapsulated contents. Reproduced with permission from ref. 134 © the Royal Society of Chemistry. (C) Representative photographs of mouse footpads infected with cutaneous *L. Major* 12 days after regimens of saline, antimonial, and ZnDPA. Reproduced with permission from ref. 136 © American Society for Microbiology. (D) Agar plates with *E. coli* (–) bacteria treated with photosensitizer conjugated ZnDPA (**mDestroy**) in the presence and absence of light treatment.

Another therapeutic concept is targeted photodynamic inactivation using photosensitizer appended with ZnDPA units. Photodynamic inactivation is an attractive antimicrobial strategy for blood sterilization and surface decontamination with the potential advantage of killing antibiotic-resistant bacteria with no apparent induction of resistance. We designed two structurally related optical probes that are conjugates of a ZnDPA unit and a BODIPY chromophore: one is a microbial targeted fluorescent imaging agent, **mSeek**, and the other is an oxygen photosensitizing analogue, **mDestroy** (Table 1).¹³⁷ The fluorescent probe, **mSeek**, is not phototoxic and enabled detection of all tested bacteria at concentrations of ~ 100 CFU mL⁻¹ for *B. thuringiensis* spores, ~ 1000 CFU mL⁻¹ for *S. aureus* and $\sim 10\,000$ CFU mL⁻¹ for *E. coli*. The photosensitizer analogue, **mDestroy**, inactivated 99–99.99% of bacterial samples and selectively killed bacterial cells in the presence of mammalian cells (Fig. 3D). However, it is worth noting that **mDestroy** was ineffective against *B. thuringiensis* spores, a genetic and structural mimic of deadly anthrax spores.

Future directions

Considering the simplicity of the ZnDPA structure, the binding selectivity for anionic cell surfaces within complex biological media is quite remarkable. One reason for this is that off-target association with polyphosphorylated biomolecules is low since most phosphorylated species are intracellular. As discussed above, imaging and therapeutic performance will be enhanced if anionic membrane affinity can be increased and further studies are warranted to achieve this goal. The development of two other desirable ZnDPA probe features is also worth future attention. One structural feature is fluorescent ZnDPA probes with ‘turn on’ emission that would allow ‘no wash’ *in vitro* assays or improved *in vivo* imaging contrast at the target site. Several of our studies have noted self-aggregation of fluorescent ZnDPA probes on the membrane surface and decreased emission intensity due to an aggregation-induced quenching effect.^{105,138} Recently, a new fluorescent ZnDPA probe with ‘aggregation-induced emission’ was reported by Hu and coworkers for apoptosis detection.¹³⁹ The deep-red probe is weakly emissive in aqueous media but turns on when it associates with the surfaces of early apoptotic mammalian cells. A near-infrared version of this type of probe would likely be very useful for *in vivo* imaging. A second desirable structural feature is the ability to cross the blood–brain barrier (BBB), which would facilitate efforts to image neurodegenerative disease. Non-invasive imaging of common pathophysiological conditions, such as Parkinson’s and Alzheimer’s disease, is greatly limited by the inability of contrast agents to cross the BBB.¹⁴⁰ To date, brain imaging with ZnDPA probes has focused on disease models that have a compromised BBB which enables probe entry.^{95,141} Nonspecific disruption of the BBB has been employed to facilitate entrance of BBB-impermeable probes into brain parenchyma, but these approaches induce uncontrolled neuronal injuries and expose the brain to circulating neuroactive and neurotoxic agents.^{140,144} ZnDPA probes have been reported

to possess high affinity for neurofibrillary tangles of hyperphosphorylated tau proteins, a component of amyloid plaques which are an established biomarker of Alzheimer’s disease.^{142,143} Radiolabeled ZnDPA probes that can safely cross the BBB are likely to be excellent tools for quantifying and diagnosing tau protein-related neurodegenerative disorders. Recent community success at formulating small molecules and nanoparticles with BBB-permeation properties is reason for pursuit and optimism.^{144–147}

Nuclear ZnDPA imaging probes should also be examined for real-time monitoring of tumorigenic cell death due to therapeutic intervention. Prescribing effective cancer treatments remains a substantial clinical challenge due to extensive heterogeneity among tumor sizes, cell type and growth behaviors from patient to patient.¹⁴⁸ There is an urgent need for technologies that can accurately and rapidly assess therapeutic response to help guide physician decision-making for personalized patient care and to assist researchers in the assessment of experimental treatments in clinical trials. Therapeutic efficacy is universally assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) which are guidelines that define when tumor burden improves (“respond”), stays the same (“stabilize”), or worsens (“progress”) during treatment.⁵⁹ These evaluations are based on size measurements before and after treatment using conventional CT or MRI anatomical imaging. While providing useful structural information, these modalities are very insensitive often requiring long intervals between imaging scans (months to years) to detect noticeable changes in tumor morphology, especially for slow-growing lesions.¹⁴⁹ Furthermore, anatomical imaging methods cannot identify tumor status (viable, necrotic, fibrotic *etc.*) and are highly limited in characterizing responses in tumors that do not change in size during therapy. Consequently, the degree of response may be underestimated or overestimated leading to incorrect conclusions.¹⁵⁰ Molecular imaging strategies are slowly becoming the standard in monitoring tumor response.¹⁵¹ For example, the PET tracer ¹⁸F-FDG, a molecular imaging agent for glucose uptake, plays an essential role in defining tumor response in malignant lymphoma by monitoring tumor cell vitality before and after treatment.^{152,153} As a complement, ZnDPA probes could be employed to monitor levels of therapeutic tumor deterioration and concurrently assess off-target cell death in organs susceptible to side effects such as the heart and liver. A dual imaging strategy can be envisioned where multiple probes simultaneously monitor tumorigenic death (ZnDPA) and active metabolism (¹⁸F-FDG), potentially offering a new methodology for promptly evaluating treatment response in solid tumors and surrounding tissue.

In terms of therapeutic applications, ZnDPA targeting of PS on dead and dying cancer cells may be a useful way to alter the immune status of tumor tissue. In general, macrophages quickly ingest apoptotic cells exposing PS and release an anti-inflammatory response, which can promote tumor growth. However, if apoptotic cells are not efficiently cleared, the surrounding tissue cells can enter secondary necrosis, a process where the plasma membrane becomes irreversibly permeable causing the release of damage-associated proteins involved in

the heat shock response and DNA organization.¹⁵⁴ The release of these proteins signals dendritic cells to acquire antigens from dead cells, which in turn induces a co-stimulatory immune response against them. Thus, it is advantageous to shift the clearance of dead and dying cells from macrophages to dendritic cells when developing treatments for cancer and other diseases. Munoz *et al.* tested this concept using annexin V to determine if blocking PS could make apoptotic cells immunogenic *in vivo*.¹⁵⁵ They discovered that annexin V inhibited cell phagocytosis by monocyte-derived macrophages, thus triggering a change in the immunogenicity of apoptotic and necrotic cells. When incubated with apoptotic tumor cells, annexin V inhibited cell clearance from macrophages initiating secondary necrosis and subsequent identification and uptake by dendritic cells.¹⁵⁶ Intravenous dosing with annexin V has been shown to reduce colorectal tumor growth, indicating PS-targeting may naturally induce tumor regression. Similar tumor regression activity has been observed with other PS-specific antibodies.^{157–159} Taken together, molecular targeting of PS on apoptotic cells may be an effective strategy for initiating a pro-inflammatory response towards tumor tissue, and ZnDPA complexes may be especially good candidates for this type of immunotherapy.

Acknowledgements

We are grateful for funding support from the NIH (RO1GM059078 to B. D. S. and T32GM075762 to D. R. R.), GAANN (K. J. C.) and technical support from the University of Notre Dame, the Notre Dame Integrated Imaging Facility, the Harper Cancer Research Institute Imaging and Flow Cytometry Core Facility, and the Freimann Life Sciences Center. The authors declare no financial conflict of interest.

References

- G. van Meer, D. R. Voelker and G. W. Feigenson, *Nat. Rev. Mol. Cell Biol.*, 2008, **9**, 112–124.
- K. Simons and J. L. Sampaio, *Cold Spring Harbor Perspect. Biol.*, 2011, **3**, a004697.
- B. K. Bradley and R. L. Schnaar, *J. Leukocyte Biol.*, 1986, **40**, 97–111.
- B. Fadeel and D. Xue, *Crit. Rev. Biochem. Mol. Biol.*, 2009, **44**, 264–277.
- Y. Uchida, J. Hasegawa, D. Chinnapen, T. Inoue, S. Okazaki, R. Kato, S. Wakatsuki, R. Misaki, M. Koike, Y. Uchiyama, S. Iemura, T. Natsume, R. Kuwahara, T. Nakagawa, K. Nishikawa, K. Mukai, E. Miyoshi, N. Taniguchi, D. Sheff, W. I. Lencer, T. Taguchi and H. Arai, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 15846–15851.
- S. H. Lee, X. W. Meng, K. S. Flatten, D. A. Loegering and S. H. Kaufmann, *Cell Death Differ.*, 2013, **20**, 64–76.
- B. R. Lentz, *Prog. Lipid Res.*, 2003, **42**, 423–438.
- P. A. Leventis and S. Grinstein, *Annu. Rev. Biophys.*, 2010, **39**, 407–427.
- K. Schutters and C. Reutelingsperger, *Apoptosis*, 2010, **15**, 1072–1082.
- H. A. Quigley, R. W. Nickells, L. A. Kerrigan, M. E. Pease, D. J. Thibault and D. J. Zack, *Invest. Ophthalmol. Visual Sci.*, 1995, **36**, 774–786.
- S. Okisaka, A. Murakami, A. Mizukawa and J. Ito, *Jpn. J. Ophthalmol.*, 1997, **41**, 84–88.
- J. Galvao, B. M. Davis and M. F. Cordeiro, *Curr. Opin. Pharmacol.*, 2013, **13**, 123–127.
- S. Eda and I. W. Sherman, *Cell. Physiol. Biochem.*, 2002, **12**, 373–384.
- Z. Yasin, S. Witting, M. B. Palascak, C. H. Joiner, D. L. Rucknagel and R. S. Franco, *Blood*, 2003, **102**, 365–370.
- E. Porreca, M. Marchisio, M. Di Nisio, V. Moretta, P. Lanuti, L. Pierdomenico, F. Cuccurullo and S. Miscia, *Thromb. Res.*, 2009, **124**, 502–504.
- J. Connor, C. Bucana, I. J. Fidler and A. J. Schroit, *Proc. Natl. Acad. Sci. U. S. A.*, 1989, **86**, 3184–3188.
- H. Schroder-Born, R. Bakalova and J. Andra, *FEBS Lett.*, 2005, **579**, 6128–6134.
- T. Utsugi, A. J. Schroit, J. Connor, C. D. Bucana and I. J. Fidler, *Cancer Res.*, 1991, **51**, 3062–3066.
- H. Woehlecke, A. Pohl, N. Alder-Baerens, H. Lage and A. Herrmann, *Biochem. J.*, 2003, **376**, 489–495.
- R. F. Zwaal, P. Comfurius and E. M. Bevers, *Cell. Mol. Life Sci.*, 2005, **62**, 971–988.
- R. F. Zwaal and A. J. Schroit, *Blood*, 1997, **89**, 1121–1132.
- M. Sugimura, R. Donato, V. V. Kakkar and M. F. Scully, *Blood Coagul. Fibrinolysis*, 1994, **5**, 365–373.
- L. V. Rao, J. F. Tait and A. D. Hoang, *Thromb. Res.*, 1992, **67**, 517–531.
- M. L. Huynh, V. A. Fadok and P. M. Henson, *J. Clin. Invest.*, 2002, **109**, 41–50.
- A. Amara and J. Mercer, *Nat. Rev. Microbiol.*, 2015, **13**, 461–469.
- L. Maruri-Avidal, A. S. Weisberg and B. Moss, *J. Virol.*, 2013, **87**, 12313–12326.
- M. Lorizate, T. Sachsenheimer, B. Glass, A. Habermann, M. J. Gerl, H. G. Krausslich and B. Brugger, *Cell. Microbiol.*, 2013, **15**, 292–304.
- G. D. Fairn, N. L. Schieber, N. Ariotti, S. Murphy, L. Kuerschner, R. I. Webb, S. Grinstein and R. G. Parton, *J. Cell Biol.*, 2011, **194**, 257–275.
- J. Mercer and A. Helenius, *Ann. N. Y. Acad. Sci.*, 2010, **1209**, 49–55.
- P. Vanlandschoot and G. Leroux-Roels, *Trends Immunol.*, 2003, **24**, 144–147.
- M. K. Callahan, P. M. Popernack, S. Tsutsui, L. Truong, R. A. Schlegel and A. J. Henderson, *J. Immunol.*, 2003, **170**, 4840–4845.
- A. S. Richard, A. Zhang, S. J. Park, M. Farzan, M. Zong and H. Choe, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, 14682–14687.
- J. L. Wanderley, A. Benjamin, F. Real, A. Bonomo, M. E. Moreira and M. A. Barcinski, *Braz. J. Med. Biol. Res.*, 2005, **38**, 807–812.
- M. K. Wassef, T. B. Fioretti and D. M. Dwyer, *Lipids*, 1985, **20**, 108–115.
- J. L. Wanderley, P. E. Thorpe, M. A. Barcinski and L. Soong, *Parasite Immunol.*, 2013, **35**, 109–119.
- R. H. Glew, A. K. Saha, S. Das and A. T. Remaley, *Microbiol. Rev.*, 1988, **52**, 412–432.
- S. J. Turco and A. Descoteaux, *Annu. Rev. Microbiol.*, 1992, **46**, 65–94.
- A. Weingartner, G. Kemmer, F. D. Muller, R. A. Zampieri, M. Gonzaga dos Santos, J. Schiller and T. G. Pomorski, *PLoS One*, 2012, **7**, e42070.
- P. A. Nguewa, M. A. Fuertes, B. Valladares, C. Alonso and J. M. Perez, *Trends Parasitol.*, 2004, **20**, 375–380.
- J. L. Wanderley, M. E. Moreira, A. Benjamin, A. C. Bonomo and M. A. Barcinski, *J. Immunol.*, 2006, **176**, 1834–1839.
- T. A. Santos, A. Portes Jde, J. C. Damasceno-Sa, L. A. Caldas, W. Souza, R. A. Damatta and S. H. Seabra, *PLoS One*, 2011, **6**, e27867.
- J. G. Montoya and O. Liesenfeld, *Lancet*, 2004, **363**, 1965–1976.
- M. A. Czuczman, R. Fattouh, J. M. van Rijn, V. Canadien, S. Osborne, A. M. Muise, V. K. Kuchroo, D. E. Higgins and J. H. Brumell, *Nature*, 2014, **509**, 230–234.
- C. Ratledge and S. G. Wilkinson, *Microbial Lipids Volume One*, Academic Press Inc., San Diego, CA, 1988.
- J. W. Rosch, F. F. Hsu and M. G. Caparon, *J. Bacteriol.*, 2007, **189**, 801–806.
- C. W. Haest, J. de Gier, J. O. den Kamp, P. Bartels and L. L. van Deenen, *Biochim. Biophys. Acta*, 1972, **255**, 720–733.
- C. R. Rietz, *Microbiol. Rev.*, 1978, **42**, 614–659.
- B. Lugtenberg and L. Van Alphen, *Biochim. Biophys. Acta*, 1983, **737**, 51–115.
- M. J. Osborn, J. E. Gander, E. Parisi and J. Carson, *J. Biol. Chem.*, 1972, **247**, 3962–3972.
- L. P. Kotra, D. Golemi, N. A. Amro, G. Y. Liu and S. Mobashery, *J. Am. Chem. Soc.*, 1999, **121**, 8707–8711.

- 51 C. R. H. Raetz and C. Whitfield, *Annu. Rev. Biochem.*, 2002, **71**, 635–700.
- 52 C. R. H. Raetz, C. M. Reynolds, M. S. Trent and R. E. Bishop, *Annu. Rev. Biochem.*, 2007, **76**, 295–329.
- 53 S. Ghosal, T. J. Leighton, K. E. Wheeler, I. D. Hutcheon and P. K. Weber, *Appl. Environ. Microbiol.*, 2010, **76**, 3275–3282.
- 54 T. J. Silhavy, D. Kahne and S. Walker, *Cold Spring Harbor Perspect. Biol.*, 2010, **2**, a000414.
- 55 T. Ebenhan, O. Gheysens, H. G. Kruger, J. R. Zeevaart and M. M. Sathekge, *BioMed Res. Int.*, 2014, **2014**, 867381.
- 56 V. Kersemans and B. Cornelissen, *Pharmaceuticals*, 2010, **3**, 600–620.
- 57 J. L. Zaro and W. C. Shen, *Front. Chem. Sci. Eng.*, 2015, **9**, 407–427.
- 58 F. F. An, W. Cao and X. J. Liang, *Adv. Healthcare Mater.*, 2014, **3**, 1162–1181.
- 59 E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe and J. Verweij, *Eur. J. Cancer*, 2009, **45**, 228–247.
- 60 K. L. Brown and R. E. Hancock, *Curr. Opin. Immunol.*, 2006, **18**, 24–30.
- 61 P. DeRose, P. E. Thorpe and D. E. Gerber, *Immunotherapy*, 2011, **3**, 933–944.
- 62 H. Boersma, B. L. Kietselaer, L. M. Stolk, A. Bennaghmouch, L. Hofstra, J. Narula, G. A. Heidendal and C. P. Reutelingsperger, *J. Nucl. Med.*, 2005, **46**, 2035–2050.
- 63 J. Hou, Y. Fu, J. Zhou, W. Li, R. Xie, F. Cao, G. E. Gilbert and J. Shi, *Vox Sang.*, 2011, **100**, 187–195.
- 64 W. Fang, F. Wang, S. Ji, X. Zhu, H. T. Meier, R. S. Hellman, K. M. Brindle, B. Davletov and M. Zhao, *Nucl. Med. Biol.*, 2007, **34**, 917–923.
- 65 M. P. Murphy and R. A. Smith, *Annu. Rev. Pharmacol. Toxicol.*, 2007, **47**, 629–656.
- 66 S. Simoes, A. Filipe, H. Faneca, M. Mano, N. Penacho, N. Duzgunes and M. P. de Lima, *Expert Opin. Drug. Delivery*, 2005, **2**, 237–254.
- 67 H. Zheng, F. Wang, Q. Wang and J. Gao, *J. Am. Chem. Soc.*, 2011, **133**, 15280–15283.
- 68 C. Xiong, K. Brewer, S. Song, R. Zhang, W. Lu, X. Wen and C. Li, *J. Med. Chem.*, 2011, **54**, 1825–1835.
- 69 Y. Marcus, *Ion Properties*, Marcel Dekker, New York, Basel, 1997.
- 70 S. Biniecki and S. Kabzinska, *Ann. Pharm. Fr.*, 1964, **22**, 685–687.
- 71 S. C. Burdette, G. K. Walkup, B. Spingler, R. Y. Tsien and S. J. Lippard, *J. Am. Chem. Soc.*, 2001, **123**, 7831–7841.
- 72 C. J. Chang and S. J. Lippard, *Neurodegenerative Diseases and Metal Ions*, John Wiley & Sons, Ltd, 2006, pp. 321–370.
- 73 X. A. Zhang, K. S. Lovejoy, A. Jasanoff and S. J. Lippard, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 10780–10785.
- 74 E. J. O'Neil and B. D. Smith, *Coord. Chem. Rev.*, 2006, **250**, 3068–3080.
- 75 A. Ojida, Y. Mito-Oka, M. A. Inoue and I. Hamachi, *J. Am. Chem. Soc.*, 2002, **124**, 6256–6258.
- 76 A. Ojida, Y. Mito-oka, K. Sada and I. Hamachi, *J. Am. Chem. Soc.*, 2004, **126**, 2454–2463.
- 77 H. Nonaka, S. Tsukiji, A. Ojida and I. Hamachi, *J. Am. Chem. Soc.*, 2007, **129**, 15777–15779.
- 78 A. Ojida and I. Hamachi, *Bull. Chem. Soc. Jpn.*, 2006, **79**, 35–46.
- 79 A. Ojida, S. Park, Y. Mito-oka and I. Hamachi, *Tetrahedron Lett.*, 2002, **43**, 6193–6195.
- 80 H. W. Rhee, H. Y. Choi, K. Han and J. I. Hong, *J. Am. Chem. Soc.*, 2007, **129**, 4524–4525.
- 81 H. T. Ngo, X. Liu and K. A. Jolliffe, *Chem. Soc. Rev.*, 2012, **41**, 4928–4965.
- 82 *Synthetic Receptors for Biomolecules: Design Principles and Applications*, ed. B. Smith, Royal Society of Chemistry, Cambridge, 2015.
- 83 T. Minami, T. Minamiki and S. Tokito, *Chem. Lett.*, 2016, **45**, 371–373.
- 84 F. J. Williams and D. Fiedler, *ACS Chem. Biol.*, 2015, **10**, 1958–1963.
- 85 J. H. Conway and D. Fiedler, *Angew. Chem.*, 2015, **54**, 3941–3945.
- 86 A. V. Koulov, K. A. Stucker, C. Lakshmi, J. P. Robinson and B. D. Smith, *Cell Death Differ.*, 2003, **10**, 1357–1359.
- 87 A. V. Koulov, R. G. Hanshaw, K. A. Stucker, C. Lakshmi and B. D. Smith, *Isr. J. Chem.*, 2005, **45**, 373–379.
- 88 C. Lakshmi, R. G. Hanshaw and B. D. Smith, *Tetrahedron*, 2004, **60**, 11307–11315.
- 89 R. G. Hanshaw, C. Lakshmi, T. N. Lambert, J. R. Johnson and B. D. Smith, *ChemBioChem*, 2005, **6**, 2214–2220.
- 90 J. M. Kwong, C. Hoang, R. T. Dukes, R. W. Yee, B. D. Gray, K. Y. Pak and J. Caprioli, *Invest. Ophthalmol. Visual Sci.*, 2014, **55**, 4913–4921.
- 91 A. M. Smith, M. C. Mancini and S. Nie, *Nat. Nanotechnol.*, 2009, **4**, 710–711.
- 92 S. B. Cui, *Acta Math. Sci.*, 2006, **26**, 781–796.
- 93 B. A. Smith, S. Xiao, W. Wolter, J. Wheeler, M. A. Suckow and B. D. Smith, *Apoptosis*, 2011, **16**, 722–731.
- 94 K. Palmowski, A. Rix, W. Lederle, F. F. Behrendt, F. M. Mottaghy, B. D. Gray, K. Y. Pak, M. Palmowski and F. Kiessling, *Eur. J. Radiol.*, 2014, **24**, 363–370.
- 95 B. A. Smith, B. W. Xie, E. R. van Beek, I. Que, V. Blankevoort, S. Xiao, E. L. Cole, M. Hoehn, E. L. Kaijzel, C. W. Lowik and B. D. Smith, *ACS Chem. Neurosci.*, 2012, **3**, 530–537.
- 96 M. M. Chan, B. D. Gray, K. Y. Pak and D. Fong, *Arthritis Res. Ther.*, 2015, **17**, 50.
- 97 X. Hu, Q. Wang, Y. Liu, H. Liu, C. Qin, K. Cheng, W. Robinson, B. D. Gray, K. Y. Pak, A. Yu and Z. Cheng, *Biomaterials*, 2014, **35**, 7511–7521.
- 98 M. M. Chan and A. R. Moore, *J. Immunol.*, 2010, **184**, 6418–6426.
- 99 L. Wyffels, B. D. Gray, C. Barber, S. K. Moore, J. M. Woolfenden, K. Y. Pak and Z. Liu, *Bioorg. Med. Chem.*, 2011, **19**, 3425–3433.
- 100 H. Wang, X. Tang, G. Tang, T. Huang, X. Liang, K. Hu, H. Deng, C. Yi, X. Shi and K. Wu, *Apoptosis*, 2013, **18**, 1017–1027.
- 101 T. Sun, G. Tang, H. Tian, K. Hu, S. Yao, Y. Su and C. Wang, *Oncotarget*, 2015, **6**, 30579–30591.
- 102 B. A. Smith, K. M. Harmatys, S. Xiao, E. L. Cole, A. J. Plaunt, W. Wolter, M. A. Suckow and B. D. Smith, *Mol. Pharmaceutics*, 2013, **10**, 3296–3303.
- 103 R. G. Hanshaw, R. V. Stahelin and B. D. Smith, *Chemistry*, 2008, **14**, 1690–1697.
- 104 A. J. Plaunt, K. M. Harmatys, W. R. Wolter, M. A. Suckow and B. D. Smith, *Bioconjugate Chem.*, 2014, **4**, 727–737.
- 105 K. J. Clear, K. M. Harmatys, D. R. Rice, W. R. Wolter, M. A. Suckow, Y. Wang, M. Ruscowski and B. D. Smith, *Bioconjugate Chem.*, 2016, **27**, 363–375.
- 106 H. Jiang, E. J. O'Neil, K. M. DiVittorio and B. D. Smith, *Org. Lett.*, 2005, **7**, 3013–3016.
- 107 H. Nonaka, S.-h. Fujishima, S.-h. Uchinomiya, A. Ojida and I. Hamachi, *J. Am. Chem. Soc.*, 2010, **132**, 9301–9309.
- 108 A. Ojida, K. Honda, D. Shinmi, S. Kiyonaka, Y. Mori and I. Hamachi, *J. Am. Chem. Soc.*, 2006, **128**, 10452–10459.
- 109 K. Honda, E. Nakata, A. Ojida and I. Hamachi, *Chem. Commun.*, 2006, 4024–4026.
- 110 B. Swaminathan and P. Feng, *Annu. Rev. Microbiol.*, 1994, **48**, 401–426.
- 111 R. T. Noble and S. B. Weisberg, *J. Water Health*, 2005, **3**, 381–392.
- 112 A. Ahmed, J. V. Rushworth, N. A. Hirst and P. A. Millner, *Clin. Microbiol. Rev.*, 2014, **27**, 631–646.
- 113 W. M. Leevy, J. R. Johnson, C. Lakshmi, J. Morris, M. Marquez and B. D. Smith, *Chem. Commun.*, 2006, 1595–1597.
- 114 V. Ganesh, K. Bodewits, S. J. Bartholdson, D. Natale, D. J. Campopiano and J. C. Mareque-Rivas, *Angew. Chem., Int. Ed.*, 2009, **48**, 356–360.
- 115 K. M. DiVittorio, W. M. Leevy, E. J. O'Neil, J. R. Johnson, S. Vakulenko, J. D. Morris, K. D. Rosek, N. Serazin, S. Hilkert, S. Hurley, M. Marquez and B. D. Smith, *ChemBioChem*, 2008, **9**, 286–293.
- 116 W. M. Leevy, S. T. Gammon, H. Jiang, J. R. Johnson, D. J. Maxwell, E. N. Jackson, M. Marquez, D. Piwnicka-Worms and B. D. Smith, *J. Am. Chem. Soc.*, 2006, **128**, 16476–16477.
- 117 A. G. White, B. D. Gray, K. Y. Pak and B. D. Smith, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 2833–2836.
- 118 J. J. Lee, A. G. White, J. M. Baumes and B. D. Smith, *Chem. Commun.*, 2010, **46**, 1068–1069.
- 119 A. G. White, N. Fu, W. M. Leevy, J. J. Lee, M. A. Blasco and B. D. Smith, *Bioconjugate Chem.*, 2010, **21**, 1297–1304.
- 120 R. H. Rubin and A. J. Fischman, *Clin. Infect. Dis.*, 1996, **22**, 414–423.
- 121 S. J. Goldsmith and S. Vallabhajosula, *Semin. Nucl. Med.*, 2009, **39**, 2–10.
- 122 A. Bunschoten, M. M. Welling, M. F. Termaat, M. Sathekge and F. W. van Leeuwen, *Bioconjugate Chem.*, 2013, **24**, 1971–1989.
- 123 T. A. Sasser, A. E. Van Avermaete, A. White, S. Chapman, J. R. Johnson, T. Van Avermaete, S. T. Gammon and W. M. Leevy, *Curr. Top. Med. Chem.*, 2013, **13**, 479–487.

- 124 X. Liu, D. Cheng, B. D. Gray, Y. Wang, A. Akalin, M. Rusckowski, K. Y. Pak and D. J. Hnatowich, *Nucl. Med. Biol.*, 2012, **39**, 709–714.
- 125 D. R. Rice, A. J. Plaunt, S. Turkyilmaz, M. Smith, Y. Wang, M. Rusckowski and B. D. Smith, *Mol. Imaging Biol.*, 2015, **17**, 204–213.
- 126 L. M. Matosziuk, A. S. Harney, K. W. Macrenaris and T. J. Meade, *Eur. J. Inorg. Chem.*, 2012, 2099–2107.
- 127 S. Xiao, L. Abu-Esba, S. Turkyilmaz, A. G. White and B. D. Smith, *Theranostics*, 2013, **3**, 658–666.
- 128 W. M. Leevy, T. N. Lambert, J. R. Johnson and B. D. Smith, *Chem. Commun.*, 2008, 2331–2333.
- 129 K. Y. Choi, O. F. Silvestre, X. Huang, K. H. Min, G. P. Howard, N. Hida, A. J. Jin, N. Carvajal, S. W. Lee, J. I. Hong and X. Chen, *ACS Nano*, 2014, **8**, 4559–4570.
- 130 K. Y. Choi, O. F. Silvestre, X. Huang, N. Hida, G. Liu, D. N. Ho, S. Lee, S. W. Lee, J. I. Hong and X. Chen, *Nat. Protoc.*, 2014, **9**, 1900–1915.
- 131 J. J. Lee, K. J. Jeong, M. Hashimoto, A. H. Kwon, A. Rwei, S. A. Shankarappa, J. H. Tsui and D. S. Kohane, *Nano Lett.*, 2014, **14**, 1–5.
- 132 E. A. Azzopardi, E. L. Ferguson and D. W. Thomas, *J. Antimicrob. Chemother.*, 2013, **68**, 257–274.
- 133 W. Gao, S. Thamphiwatana, P. Angsantikul and L. Zhang, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2014, **6**, 532–547.
- 134 A. J. Plaunt, M. B. Courbanou, K. D. Cuisson, K. M. Harmatys and B. D. Smith, *Chem. Commun.*, 2012, **48**, 8123–8125.
- 135 A. J. Plaunt, K. M. Harmatys, K. A. Hendrie, A. J. Musso and B. D. Smith, *RSC Adv.*, 2014, **4**, 57983–57990.
- 136 D. R. Rice, P. Vacchina, B. Norris-Mullins, M. A. Morales and B. D. Smith, *Antimicrob. Agents Chemother.*, 2016, **60**, 2932–2940.
- 137 D. R. Rice, H. Gan and B. D. Smith, *Photochem. Photobiol. Sci.*, 2015, **14**, 1271–1281.
- 138 Y. Suzuki and K. Yokoyama, *J. Am. Chem. Soc.*, 2005, **127**, 17799–17802.
- 139 Q. Hu, M. Gao, G. Feng, X. Chen and B. Liu, *ACS Appl. Mater. Interfaces*, 2015, **7**, 4875–4882.
- 140 W. M. Pardridge, *NeuroRx*, 2005, **2**, 3–14.
- 141 C. Chu, X. Huang, C. T. Chen, Y. Zhao, J. J. Luo, B. D. Gray, K. Y. Pak and N. J. Dun, *Mol. Imaging*, 2013, **12**, 8–16.
- 142 A. Ojida, T. Sakamoto, M. A. Inoue, S. H. Fujishima, G. Lippens and I. Hamachi, *J. Am. Chem. Soc.*, 2009, **131**, 6543–6548.
- 143 H. Y. Kim, U. Sengupta, P. Shao, M. J. Guerrero-Munoz, R. Kayed and M. Bai, *Am. J. Nucl. Med. Mol. Imaging*, 2013, **3**, 102–117.
- 144 J. L. Mikitsh and A. M. Chacko, *Perspect. Med. Chem.*, 2014, **6**, 11–24.
- 145 R. M. Koffie, C. T. Farrar, L.-J. Saidi, C. M. William, B. T. Hyman and T. L. Spires-Jones, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 18837–18842.
- 146 B. J. Bacskaï, W. E. Klunk, C. A. Mathis and B. T. Hyman, *J. Cereb. Blood Flow Metab.*, 2002, **22**, 1035–1041.
- 147 M. Ono and H. Saji, *Int. J. Mol. Imaging*, 2011, **2011**, 543267.
- 148 R. Fisher, L. Pusztai and C. Swanton, *Br. J. Cancer*, 2013, **108**, 479–485.
- 149 S. Y. El Sharouni, H. B. Kal and J. J. Battermann, *Br. J. Cancer*, 2003, **89**, 2184–2189.
- 150 K. R. Birchard, J. K. Hoang, J. E. Herndon, Jr. and E. F. Patz, Jr., *Cancer*, 2009, **115**, 581–586.
- 151 E. L. van Persijn van Meerten, H. Gelderblom and J. L. Bloem, *Eur. J. Radiol.*, 2010, **20**, 1456–1467.
- 152 W. A. Weber, *J. Nucl. Med.*, 2009, **50**(suppl 1), 1S–10S.
- 153 R. L. Wahl, H. Jacene, Y. Kasamon and M. A. Lodge, *J. Nucl. Med.*, 2009, **50**(suppl 1), 122S–150S.
- 154 L. Zitvogel, O. Kepp and G. Kroemer, *Cell*, 2010, **140**, 798–804.
- 155 L. E. Munoz, S. Franz, F. Pausch, B. Furnrohr, A. Sheriff, B. Vogt, P. M. Kern, W. Baum, C. Stach, D. von Laer, B. Brachvogel, E. Poschl, M. Herrmann and U. S. Gaipf, *J. Leukocyte Biol.*, 2007, **81**, 6–14.
- 156 B. Frey, P. Schildkopf, F. Rodel, E. M. Weiss, L. E. Munoz, M. Herrmann, R. Fietkau and U. S. Gaipf, *J. Immunotoxicol.*, 2009, **6**, 209–216.
- 157 X. Huang, M. Bennett and P. E. Thorpe, *Cancer Res.*, 2005, **65**, 4408–4416.
- 158 A. W. Beck, T. A. Luster, A. F. Miller, S. E. Holloway, C. R. Conner, C. C. Barnett, P. E. Thorpe, J. B. Fleming and R. A. Brekken, *Int. J. Cancer*, 2006, **118**, 2639–2643.
- 159 J. He, Y. Yin, T. A. Luster, L. Watkins and P. E. Thorpe, *Clin. Cancer Res.*, 2009, **15**, 6871–6880.